The role of immune checkpoint inhibitors and/or Yttrium-90 radioembolization in the management of hepatocellular carcinoma: challenges of treatment sequence

Abstract

Hepatocellular carcinoma (HCC) is an aggressive primary liver cancer secondary to chronic liver disease or cirrhosis. In the setting of chronic inflammation, the liver’s tightly regulated immune system is disrupted, resulting in immune cell fatigue. This makes the liver vulnerable to tumorigenesis. Surgery and/or transplantation offer the best long-term survival for patients diagnosed with early HCC. Unfortunately, patients commonly develop recurrent or metastatic disease. Some patients will present with unresectable HCC or liver dysfunction. As such, locoregional therapy options may be limited. Research is focused on leveraging the distinctive liver immune microenvironment and its role in HCC carcinogenesis for the development of more effective systemic therapies. Given the success of immunotherapy in treating advanced HCC, the scientific community is looking to expand the indications of immunotherapy to the neoadjuvant and/or adjuvant setting and in combination with other locoregional therapies. We herein review the most recent data on the use of neoadjuvant or adjuvant immunotherapy and its combination with Yttrium-90 (Y90) radioembolization for HCC for curative intent.

Keywords

Hepatocellular carcinoma / immunotherapy / Yttrium-90 / Y90 / radioembolization

References

[1] Robinson MW,O’Farrelly C.Liver immunology and its role in inflammation and homeostasis.Cell Mol Immunol2016;13:267-76 PMCID:PMC4856809

[2] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.J Hepatol2022;76:681-93 PMCID:PMC8866082

[3] De Castro T,Bathon M.Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.Ther Adv Med Oncol2022;14:17588359221080298 PMCID:PMC8891886

[4] Finn RS,Ikeda M.IMbrave150 investigatorsAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[5] Abou-Alfa GK,Kudo M.Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.NEJM Evidence2022;8:EVIDoa2100070

[6] Llovet JM,Kulik L.Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2021;18:293-313

[7] Benson AB 3rd,Ben-Josef E.NCCN clinical practice guidelines in oncology: hepatobiliary cancers.JNCCN2009;7:350-91 PMCID:PMC4461147

[8] Kokudo N,Hasegawa K.Clinical practice guidelines for hepatocellular carcinoma: the japan society of hepatology 2017 (4th jsh-hcc guidelines) 2019 update.Hepatol Res2019;49:1109-13

[9] Franzin R,Spadaccino F.The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand?.Front Immunol2020;11:574271 PMCID:PMC7580288

[10] He X.Immune checkpoint signaling and cancer immunotherapy.Cell Res2020;30:660-9 PMCID:PMC7395714

[11] Gao Y,Yang C.Overcoming T cell exhaustion via immune checkpoint modulation with a dendrimer-based hybrid nanocomplex.Adv Healthc Mater2021;10:e2100833

[12] Mohr R,Özdirik B.Lessons from immune checkpoint inhibitor trials in hepatocellular carcinoma.Front Immunol2021;12:652172 PMCID:PMC8042255

[13] Rotte A.Combination of CTLA-4 and PD-1 blockers for treatment of cancer.J Exp Clin Cancer Res2019;38:255 PMCID:PMC6567914

[14] Wu Y,Huang A,Liu Y.CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.J Exp Med1997;185:1327-35 PMCID:PMC2196265

[15] Onuma AE,Huang H,Noonan A.Immune checkpoint inhibitors in hepatocellular cancer: current understanding on mechanisms of resistance and biomarkers of response to treatment.Gene Expr2020;20:53-65 PMCID:PMC7284108

[16] Kassel R,Iezzoni JC,Pruett TL.Chronically inflamed livers up-regulate expression of inhibitory B7 family members.Hepatology2009;50:1625-37 PMCID:PMC2897253

[17] Wang BJ,Wang JZ.Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.World J Gastroenterol2011;17:3322-9 PMCID:PMC3160536

[18] Marron TU,Hamon P.Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.Lancet Gastroenterol Hepatol2022;7:219-29 PMCID:PMC9901534

[19] Xia Y,Qian X.Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.J Immunother Cancer2022;10:e004656 PMCID:PMC8981365

[20] Kaseb AO,Cao HST.Perioperative nivolumab monotherapy vs. nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.Lancet Gastroenterol Hepatol2022;7:208-18 PMCID:PMC8840977

[21] D’alessio A,Spalding D.Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: the PRIME-HCC trial.JCO2022;40:4093

[22] Zhu XD,Shen YH.Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations.Liver Cancer2021;10:320-9 PMCID:PMC8339461

[23] Zhang W,Han J.Surgery after conversion therapy with PD-1 inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: a pilot study of ten patients.Front Oncol2021;11:747950 PMCID:PMC8560793

[24] Ho WJ,Durham J.Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity.Nat Cancer2021;2:891-903 PMCID:PMC8594857

[25] Xu XF,Han J.Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from china.JAMA Surg2019;154:209-17 PMCID:PMC6439634

[26] Hack SP,Chen M.IMbrave 050: a phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.Future Oncol2020;16:975-89

[27] Chow P,Cheng A.Abstract CT003: IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab vs. active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.Cancer Research2023;83:CT003

[28] Ogino S,Hamada T,Nishihara R.Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology.Annu Rev Pathol2019;14:83-103 PMCID:PMC6345592

[29] Gunjur A,Klein O.‘Know thyself’ - host factors influencing cancer response to immune checkpoint inhibitors.J Pathol2022;257:513-25 PMCID:PMC9320825

[30] Hiroishi K,Baba T.Strong CD8⁺ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma.J Gastroenterol2010;45:451-8

[31] Nobuoka D,Shirakawa H.Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.Int J Oncol2012;40:63-70

[32] Hansler J,Schuppan D.Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases.World J Gastroenterol2006;12:3716-21 PMCID:PMC4087464

[33] Ayaru L,Alisa A.Unmasking of alpha-fetoprotein-specific CD4⁺ T cell responses in hepatocellular carcinoma patients undergoing embolization.J Immunol2007;178:1914-22

[34] Rapoport BL.Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy.Int J Mol Sci2019;20:959 PMCID:PMC6412296

[35] Basu S,Suto R,Srivastava PK.Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway.Int Immunol2000;12:1539-46

[36] Roberts EW,Binnewies M.Critical Role for CD103⁺/CD141⁺ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma.Cancer Cell2016;30:324-36 PMCID:PMC5374862

[37] Salem R,Kim E.Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY Study.Hepatology2021;74:2342-52 PMCID:PMC8596669

[38] Salem R,Mouli S.Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma.Gastroenterology2016;151:1155-63.e2

[39] Ali R,Abouchaleh N.Survival analysis of advanced HCC treated with radioembolization: comparing impact of clinical performance status vs. vascular invasion/metastases.Cardiovasc Intervent Radiol2018;41:260-9

[40] Abouchaleh N,Ali R.⁹⁰Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort.J Nucl Med2018;59:1042-8

[41] Vilgrain V,Assenat E.Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.Lancet Oncol2017;18:1624-36

[42] Viñal D,Prieto I,Rodriguez-Salas N.Ytrrium-90 transarterial radioembolization in patients with gastrointestinal malignancies.Clin Transl Oncol2022;24:796-808

[43] Chew V,Pan L.Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma.Gut2019;68:335-46 PMCID:PMC6352403

[44] Rivoltini L,Camisaschi C.Y⁹⁰-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers.Gut2023;72:406-7 PMCID:PMC9872224

[45] Zhan C,Shanbhogue KP.Safety of combined Yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma.J Vasc Interv Radiol2020;31:25-34

[46] Marinelli B,Pasik SD.Safety and efficacy of locoregional treatment during immunotherapy with nivolumab for hepatocellular carcinoma: a retrospective study of 41 interventions in 29 patients.J Vasc Interv Radiol2020;31:1729-38.e1

[47] Yu Q,Ungchusri E.Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: a preliminary report of safety and feasibility.J Interv Med2023;6:187-93 PMCID:PMC10831372

[48] Villalobos A,Little O.Safety and efficacy of concurrent atezolizumab/bevacizumab or nivolumab combination therapy with Yttrium-90 radioembolization of advanced unresectable hepatocellular carcinoma.Curr Oncol2023;30:10100-10 PMCID:PMC10742675

[49] Tai D,Gogna A.Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.Lancet Gastroenterol Hepatol2021;6:1025-35

[50] Garcia-Reyes K,Menon KM.Radioembolization plus immune checkpoint inhibitor therapy compared with radioembolization plus tyrosine kinase inhibitor therapy for the treatment of hepatocellular carcinoma.J Vasc Interv Radiol2024;35:722-30.e1

[51] Yu S,Keane B.A pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma.Oncologist2024;29:270-e413 PMCID:PMC10911903